This triple mechanism distinguishes it from existing agents such as semaglutide (a GLP-1 receptor agonist) or tirzepatide (a dual GIP/GLP-1 agonist), and is hypothesised to produce more pronounced metabolic effects, particularly in the liver
For those exploring alternative delivery methods, oral semaglutide drops and tirzepatide drops represent different absorption pathways that may produce different digestive effect profiles
Novo Nordisk, the manufacturer of the original drug, which owns the patent on semaglutide, is working alongside the FDA to test the seized drugs
Santos LO, Silva PGP, Junior L, de Oliveira WJF, V
doi: 10.1080/10408398.2018.1542587 39 HolscherHD
Food and Drug Administration (2019)